000			04333cam a2200397Ii 4500
001			95801
003			ES-MaUEC
005			20230102112722.0
006			m o d
007			cr cnu|||unuuu
008			170413s2017 nyua o 001 0 eng d
020			_a1441907173 _q(electronic bk.)
020			_a1441907181 _q(print and electronic bundle)
020			_a9781441907172 _q(electronic bk.)
020			_a9781441907189 _q(print and electronic bundle)
020			_z9781441907165 _q(print)
040			_aGW5XE _cGW5XE _dOCLCF _dYDX _dUAB _dMERER _dAZU _dESU _dIOG _dOCLCQ _dVT2 _dCOO _dAUD _dOTZ _dNJR _dJG0 _dU3W _dES-MaUEC _bspa
050		4	_aRC268.4 _bC363 2017 EB
066			_c(S
245	0	0	_aCancer therapeutic targets _cJohn L. Marshall, editor.
264		1	_aNew York, NY _bSpringer _c2017.
300			_a1 recurso en línea _bilustraciones (algunas a color)
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_atext file _bPDF _2rda
500			_aIncluye índice
500			_aSpringerLink _bSpringer Biomedical and Life Sciences eBooks 2017 English+International
520	3		_aIn the past decade, we have experienced an explosion of new information about cancer therapeutic targets. Many of the targets have been validated by the discovery and approval of new medicines which have been approved for the treatment of cancer. On the heels of these successes, innumerable new targets and new potential therapeutics are being developed by many different groups including government agencies, pharmaceutical companies, biotechnology companies, academic institutions, and individual investigators. Understanding the expanding "universe" of cancer therapies is therefore becoming impossible and no single source exists which serves as a reference for the involved parties. Further, the interested parties have vastly different areas of expertise, from focused laboratory based science, to clinical research, to corporate and regulatory oversight. The text would be updated every two years, more often depending on pace of change, interest and sales. While useful online, this reference book would likely be kept in hard copy as well.
650		7	_aCancer _xGenetic aspects. _2fast _0(OCoLC)fst00845368 _9139308 _0comprobar BNE19900970859
700	1		_aMarshall, John L. _q(John Lindsay), _eeditor literario
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-1-4419-0717-2 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
880	0		_6505-00 _aAKT -- Anti-4-1BB/4-1BBL -- Anti-B7-H4 -- Anti-CD40/Anti CD40L -- Anti-Idiotype antibodies -- Anti-Programmed Death 1 (PD1) -- B7.1 -- Bacterial Vaccines -- Brachyury -- CCL21 -- CD4+ T Cells -- CD8 T Cells -- CEA -- CTLA-4 -- Dendritic cells -- DNA Vaccines -- EGFR, Immunology -- Fc Gamma R -- Gangliosides -- Glucocorticoid-Induced TNF Receptor (GITR) -- GM-CSF and Whole Cells -- gp100 -- HER2/neu -- indoleamine 2,3-dioxygenase -- Integrins, Immunology -- Interferon alpha -- Interleukin 2 -- Interleukin 7 -- Interleukin 12 -- Interleukin 15 -- Interleukin 21 -- Lymphocyte Activation Gene 3 (LAG-3) -- MART-1 -- MUC1 -- NK Cells -- P53, Immunology -- PAP -- Peptide Vaccine: Overview -- Proteins (Mesothelin) -- PSA -- Survivin -- Telomerase-related proteins -- TGF Beta Receptors -- TLR7 and TLR8, Resiquimod, and 852A -- TLR9 -- Transforming Growth Factor β -- Tregs -- Tyrosinase: Overview -- VEGF -- Viral-Like Proteins -- Whole-Cell Vaccines -- FGF-FGFR Signaling in Cancer -- MMPs -- PDGF -- TIE -- VEGF A -- VEGF Ligands -- AXL -- B-Raf -- CKIT -- DNA Repair, Overview -- EGFR, Growth factors -- HER3 -- IGF 1 and IGF 2 -- Jak2/Stat5a/b Pathway in Prostate Cancer -- JNK Signaling in Diseases -- K-Ras -- MET -- NEDD9 -- N-Ras -- P38 -- Rac 1 -- Type I Insulin-Like Growth Factor Receptor -- Anti-apoptotic Bcl-2 -- BH3-Only Mimetics -- Caspase -- DR4 and DR5 -- FLIP -- MLH1 -- NF-κB -- PARP -- ROS -- X-Linked IAP -- APC -- AR, Overview -- BRCA 1 and 2 -- Cell Cycle Related Kinases -- ER -- Histone Deacetylases (HDAC) -- Methylation -- PR -- Retinoids -- Topoisomerase 1 -- Topoisomerase 2 -- VDR.
988			_aEBOOK, asignarmaterias, EBSPRINGER_2017C
998			_b02/2018 _dz _e- _zSI
999			_c95801 _d95801 _x1